Picard Medical Reports 85% Revenue Growth but Incurred $7.62 Million Net Loss in Latest Quarter

Picard Medical, Inc. (PMI) reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company generated total revenues of $1.15 million, an increase of 85% compared to $620,000 in the same period last year. This growth was primarily driven by a 54% rise in product sales, which reached $943,000, and a substantial increase in rental revenues, which surged to $207,000 from just $7,000 a year earlier. Despite this revenue growth, PMI reported a net loss of $7.62 million, up from a loss of $5.56 million in the prior year, reflecting ongoing operational challenges.

The company's operating expenses also rose significantly, totaling $4.79 million for the quarter, a 66% increase from $2.89 million in the previous year. This increase was largely attributed to heightened research and development costs, which surged by 135% to $1.90 million, as PMI continues to invest in the development of its next-generation products. Selling, general, and administrative expenses also increased by 39% to $2.89 million, driven by higher professional and legal costs.

In terms of operational metrics, PMI's customer base remains concentrated, with a significant portion of revenue derived from a limited number of clients. For the three months ended March 31, 2026, Customer A accounted for 68% of total revenue, highlighting the company's reliance on key customers. The company has also been actively managing its inventory, which stood at $7.45 million, reflecting a slight increase from $7.30 million at the end of 2025. The company reported a gross profit of $275,000, a notable improvement from a gross loss of $358,000 in the prior year.

Looking ahead, PMI faces substantial challenges, including the need for additional financing to support its operations and product development efforts. The company has indicated that it will continue to rely on equity and debt financing to meet its cash needs, which may dilute existing shareholders' interests. Furthermore, PMI has acknowledged substantial doubt about its ability to continue as a going concern, emphasizing the importance of increasing sales and securing additional funding. The company is also navigating compliance requirements following its transition to a public company, which may further impact its financial performance and operational strategies.